This application is submitted on behalf of the University of Chicago and a consortium of three affiliated community hospitals in Illinois and Indiana.
The aims of this proposal are to study new phase II agents in the treatment of solid tumors that are refractory to standard therapy including breast cancer, non-small cell lung cancer, prostate cancer, colorectal cancer head and neck cancer and renal cancer. These studies seek to establish activity of new agents in these diseases. In addition, we propose to study population pharmacokinetics and pharmacodynamics of anticancer single agents and/or combinations, and to determine their significance for treatment outcome including toxicity and response. We will seek to develop pharmacologic models that optimize the therapeutic ratio of anticancer agents and assist in individualized dosing. The proposed studies will be conducted at the University of Chicago and three affiliated hospitals. These institutions have previously worked together and have a firm track record of conducting multiinstitutional clinical research. It is expected that four phase Il trials of up to 40 patients each will be conducted on an annual basis within this consortium. In addition there is a solid institutional foundation of pharmacologically based clinical investigations of new anticancer agents. Sample protocols are provided for phase II trials of pyrazine diazo hydroxide or suramin in breast, colorectal, prostate, non-small cell lung and renal cancer, respectively. An additional sample protocol on concomitant chemoradiotherapy in head and neck cancer is provided. In each of these studies clinical activity of a new single agent or combination in a minimally pretreated patient population will be investigated. In addition, a detailed kinetic and pharmacodynamic profile will be established.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01CA063187-04S2
Application #
6127252
Study Section
Special Emphasis Panel (SRC (62))
Program Officer
Arbuck, Susan
Project Start
1994-06-01
Project End
2001-01-31
Budget Start
1999-07-21
Budget End
2001-01-31
Support Year
4
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Chicago
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
225410919
City
Chicago
State
IL
Country
United States
Zip Code
60637
Ziliak, Dana; O'Donnell, Peter H; Im, Hae Kyung et al. (2011) Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers. Transl Res 157:265-72
Horton, Terzah M; Jenkins, Gaye; Pati, Debananda et al. (2009) Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity. Mol Cancer Ther 8:2232-42
Horton, Terzah M; Thompson, Patrick A; Berg, Stacey L et al. (2007) Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study. J Clin Oncol 25:4922-8
Ryan, Christopher W; Dolan, M Eileen; Brockstein, Bruce B et al. (2006) A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma. Cancer Chemother Pharmacol 58:634-9
Winquist, Eric; Vokes, Everett; Moore, Malcolm J et al. (2005) A Phase II study of oxaliplatin in urothelial cancer. Urol Oncol 23:150-4
Mauer, A M; Kraut, E H; Krauss, S A et al. (2005) Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus. Ann Oncol 16:1320-5
Desai, Apurva A; Kindler, Hedy L; Taber, David et al. (2005) Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer. Cancer Chemother Pharmacol 56:421-6
Kindler, Hedy L; Tothy, Peter K; Wolff, Robert et al. (2005) Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers. Invest New Drugs 23:489-93
Winegarden, J D; Mauer, A M; Otterson, G A et al. (2004) A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer. Ann Oncol 15:915-20
Kindler, Hedy L; Avadhani, Anjali; Wade-Oliver, Kurombi et al. (2004) 9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium. Invest New Drugs 22:323-7

Showing the most recent 10 out of 25 publications